Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism

Nature

Volumn 386, Issue 6622, 1997, Pages 288-292

  Su, Wu Chou S ^a   Kitagawa, Motoo ^a   Xue, Ninrong ^a   Xie, Bing ^a   Garofalo, Silvio ^b   Cho, Jay ^b   Deng, Chuxia ^c   Horton, William A ^b   Fu, Xin Yuan ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Shriner's Hospital   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN P21; STAT1 PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; THANATOPHORIC DWARFISM;

ANIMALS; BONE AND BONES; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MICE; MUTATION; POINT MUTATION; PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; STAT1 TRANSCRIPTION FACTOR; THANATOPHORIC DYSPLASIA; TRANS-ACTIVATORS; TRANSFECTION;

EID: 0030896404     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/386288a0     Document Type: Article

References (30)

1. Muenke, M. & Schell, U. Fibroblast-growth-factor receptor mutaitons in human skeletal disorders. Trends Genet. 11, 308-313 (1995).
2. Darnell, J. E. Jr, Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421 (1994).
3. Ihle, J. N. & Kerr, I. M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11, 69-74 (1995).
4. Mason, I. J. The ins and outs of fibroblast growth factors. Cell 78, 547-552 (1994).
5. Tavormina, P. L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 9, 321-328 (1995).
6. Sillence, D. O., Horton, W. A. & Rimoin, D. L. Morphologic studies in the skeletal dysplasia. Am. J. Pathol. 96, 813-859 (1979).
7. Deng, C., Wynshaw-Boris, A., Zhou, R, Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).
8. Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G. & Ornitz, D. M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390-397 (1996).
9. Webster, K. M., D'avis, P. Y., Robertson, S. C. & Donoghue, D. J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16, 4081-4087 (1996).
10. Naski, M. C., Wang, Q., Xu, J. & Ornitz, D. M. Graded activation of FGFR3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 13, 233-237 (1996).
11. Fu, X.-Y. A transcription factor with SH2 and SH3 domains is directly activated by an interferon α-induced cytoplasmic protein tyrosine kinase(s). Cell 70, 323-335 (1992).
12. Shuai, K., Schindler, C., Prezioso, V. R. & Darnell, J. E. Jr Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91 kDa DNA binding protein. Science 259, 1808-1812 (1992).
13. Velazquez, L., Fellous, M., Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70, 313-322 (1992).
14. Sadowski, H. B. & Gilman, M. Z. Cell-free activation of a DNA binding protein by epidermal growth factor. Nature 362, 79-83 (1993).
15. Larner, A. C. et al. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 261, 1730-1733 (1993).
16. Fu, X.-Y. & Zhang, J.-J. Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74, 1135-1145 (1993).
17. Ruff-Jamison, S., Chen, K. & Cohen, S. Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc. Natl Acad. Sci. USA 92, 4215-4218 (1995).
18. WAF1/CIP1 mediated by STAT1. Science 272, 719-722 (1996).
19. Ornitz, D. M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267, 16305-16311 (1992).
20. Schindler, C., Shuai, K., Prezioso, V. R. & Darnell, J. E. Jr Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809-813 (1992).
21. Ko, L. O. & Prives, C p53; Puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
22. Schlessinger, J. & Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron 9, 383-391 (1992).
23. van der Geer, P., Hunter, T. & Lindberg, R. Receptor protein tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell. Biol 10, 251-337 (1994).
24. Peters, K., Ornitz, D., Werner, S. & Williams, L. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol. 155, 423-430 (1993).
25. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
26. Meraz, M. A. et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442 (1996).
27. Durbin, J. E., Hackenmiller, R., Simon, M. C. & Levy, D. E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443-450 (1996).
28. Mizushima, S. & Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18, 5332 (1990).
29. Webster, M. K. & Donoghue, D. J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520-527 (1996).
30. Yamamoto, H., Crow, M., Cheng, L., Lakatta, E. & Kinsella, J. PDGF receptor-to-nucleus signaling of p91 (STAT1 alpha) transcription factor in rat smooth muscle cells. Exp. Cell Res. 222, 125-130 (1996).